ArticleRespiratory research2026
Snhg18 promotes hypoxic pulmonary hypertension by enhancing glycolysis.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPulmonary hypertension (PH) is a life-threatening vascular disorder characterized by progressive pulmonary vascular remodeling. Emerging evidence has indicated that long non-coding RNAs (lncRNAs) play vital roles in the pathogenesis of PH. In this study, we aim to clarify the role of lncRNA small nucleolar RNA host gene 18 (Snhg18) in pulmonary vascular remodeling and investigate its underlying mechanisms.
methodsDifferential gene expression was detected by qRT-PCR and Western blot assays. CCK-8, EdU, transwell assays, and the in vivo pulmonary hypertension model were used to investigate the effect of Snhg18 on pulmonary hypertension. Dual-luciferase reporter assay, chromatin immunoprecipitation (ChIP) assay, RNA pull-down, and transcriptome sequencing were employed to explore the mechanism by which Snhg18 functions in pulmonary hypertension.
resultsLncRNA Snhg18 is upregulated in pulmonary artery smooth muscle cells (PASMCs) and lung tissues under hypoxic conditions. Inhibition of Snhg18 attenuates cell proliferation in vitro and in vivo. Mechanistically, copy number amplification promotes the expression of Snhg18 at the genomic level, and the transcription factor Sp1 activates Snhg18 transcription by binding to its promoter. Furthermore, Snhg18 interacts with the m6A "reader" protein heterogeneous nuclear ribonucleoprotein A2/B1 (Hnrnpa2b1), thus increasing the stability of enolase 3 (Eno3) mRNA in an m6A-dependent manner. The elevation of Eno3 augments glycolysis in PASMCs, thus promoting cell proliferation and vascular remodeling.
conclusionsOur study demonstrates the important role of Snhg18/Hnrnpa2b1/Eno3 axis in pulmonary vascular remodeling, and provides a potential novel therapeutic target for PH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.